The proposed TRIPs covid waiver is a bad idea that could do a lot of good

The Long Read: With Big Pharma being blamed for the slow roll-out of vaccines in medium and low-income countries, Zilber IP’s Einav Zilber argues that the debate over suspending patents, trade secrets and other rights to increase access to jabs is really about the relationship between states and drug companies – and that these issues are not going away